Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=a2e20e899e5ab994754dd16899a8a74c
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
eqs_en 
0 07.06.22
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=a2e20e899e5ab994754dd16899a8a74c
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
eqs_en 
0 07.06.22
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma


GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed

BusinessWire_EN 
0 06.08.20
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma


GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed

BusinessWire_EN 
0 06.08.20
AstraZeneca: Kurs-Irrsinn nach Impfstoff-News
AstraZeneca: Kurs-Irrsinn nach Impfstoff-News

Papiere des britischen Pharmakonzerns AstraZeneca (WKN: 886455) verteuern sich heute Morgen um zeitweise +30% auf 120 Euro. Börsenlaien lassen sich von einem am Wochenende vermeldeten Impfstoff-Deal

sharedeals 
0 15.06.20
AstraZeneca: Kurs-Irrsinn nach Impfstoff-News
AstraZeneca: Kurs-Irrsinn nach Impfstoff-News

Papiere des britischen Pharmakonzerns AstraZeneca (WKN: 886455) verteuern sich heute Morgen um zeitweise +30% auf 120 Euro. Börsenlaien lassen sich von einem am Wochenende vermeldeten Impfstoff-Deal

sharedeals 
0 15.06.20
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer


GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)

BusinessWire_EN 
0 24.04.20
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer


GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)

BusinessWire_EN 
0 24.04.20
Amarin: Vorzeitige Bescherung durch die FDA!
Amarin: Vorzeitige Bescherung durch die FDA!

Am vergangenen Freitag, dem 13. Dezember, war die Aktie von Amarin (WKN: A0NBNG) in den USA den größten Teil des Tages vom Handel ausgesetzt. Grund hierfür war eine bevorstehende, Kurs bewegende

sharedeals 
0 16.12.19
Amarin: 16:0-Kantersieg beim gestrigen FDA-Meeting
Amarin: 16:0-Kantersieg beim gestrigen FDA-Meeting

Die Aktie des irisch-amerikanischen Biotechunternehmens Amarin (WKN: A0NBNG) ist schon seit einiger Zeit vom Handel ausgesetzt. Grund für diese Handelsaussetzung war das angekündigte Treffen von

sharedeals 
0 15.11.19
Amarin: 16:0-Kantersieg bei FDA-Meeting
Amarin: 16:0-Kantersieg bei FDA-Meeting

Die Aktie des irisch-amerikanischen Biotechunternehmens Amarin (WKN: A0NBNG) ist schon seit einiger Zeit vom Handel ausgesetzt. Grund für diese Handelsaussetzung war das angekündigte Treffen von

sharedeals 
0 15.11.19
2018's 3 Biggest Catalysts for Marijuana Stocks
2018's 3 Biggest Catalysts for Marijuana Stocks
Forget seeing marijuana stocks go up in smoke in 2017. They've been smoking hot.According to cannabis research firm ArcView, the North American legal weed industry is expected to grow by 26% a....
TheMotleyFool 
0 22.12.17
3 Best Marijuana Biotech Stocks for 2018
3 Best Marijuana Biotech Stocks for 2018
Next year should be enormously important for Canadian marijuana stocks, as the country moves forward with legalization of recreational marijuana. But that milestone means little for biotechs....
TheMotleyFool 
0 22.12.17
The 3 Marijuana Stocks With the Most Cash on Their Balance Sheets
The 3 Marijuana Stocks With the Most Cash on Their Balance Sheets
There aren't too many industries that can hold a candle to the returns of cryptocurrencies these days, but the marijuana industry isn't going down without a fight. Marijuana stocks certainly have....
TheMotleyFool 
0 11.12.17
Here's What Caused This Marijuana Stock to Skyrocket 15% in November
Here's What Caused This Marijuana Stock to Skyrocket 15% in November
Medical marijuana has been used to treat epilepsy in patients for years, but so far, it's efficacy and safety hasn't been supported by a regulatory green light from the Food and Drug....
TheMotleyFool 
0 07.12.17
5 Key Things to Know About This Leading Marijuana Stock's Future
5 Key Things to Know About This Leading Marijuana Stock's Future
You can count the number of pure-play marijuana stocks with a market cap of around $3 billion on one hand -- and have several fingers left over. GW Pharmaceuticals (NASDAQ: GWPH) ranks as one of....
TheMotleyFool 
0 06.12.17
This Marijuana Stock Is Poised for a Breakout Year in 2018 -- Here's What You'll Want to Know About It
This Marijuana Stock Is Poised for a Breakout Year in 2018 -- Here's What You'll Want to Know About It
Admittedly, 2017 so far has kind of been a ho-hum year for former high-flying marijuana stock GW Pharmaceuticals (NASDAQ: GWPH). For the most part, investors have just been waiting for the next....
TheMotleyFool 
0 02.12.17
The Federal Government Just Broke Its Medical-Marijuana Promise
The Federal Government Just Broke Its Medical-Marijuana Promise
Few if any industries are growing at a quicker and more consistent pace in the U.S. than marijuana. A report released earlier this year by Marijuana Business Daily entitled "Marijuana Business....
TheMotleyFool 
0 26.11.17
Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today
Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today
After the company released updated clinical trial data showing efficacy of its marijuana drug as a monotherapy and improvement from baseline over long-term use, shares of GW....
TheMotleyFool 
0 21.11.17
The 4 Largest Pure-Play Marijuana Stocks
The 4 Largest Pure-Play Marijuana Stocks
Marijuana hasn't come by the nickname "the green rush" by accident. If we take a closer look at the performance of marijuana stocks, most have had investors seeing a lot of green over the trailing....
TheMotleyFool 
0 17.11.17
What's Behind GW Pharmaceuticals' 6.4% Gain in October?
What's Behind GW Pharmaceuticals' 6.4% Gain in October?
Shares of GW Pharmaceuticals plc (NASDAQ: GWPH), a company developing an epilepsy drug derived from its cannabinoid product platform, tacked on another 6.4% in October according to data from....
TheMotleyFool 
0 06.11.17
GW Pharmaceuticals Just Delivered Some Good News About Its Marijuana-Based Drug
GW Pharmaceuticals Just Delivered Some Good News About Its Marijuana-Based Drug
This year has been a real seesaw for shareholders of GW Pharmaceuticals (NASDAQ: GWPH). Lately, that seesaw is tipping up slightly, following news that a cannabidiol-based drug candidate the....
TheMotleyFool 
0 06.11.17
True or False: Republicans Support Legalizing Marijuana?
True or False: Republicans Support Legalizing Marijuana?
Chances are that you'd struggle to find an industry within the U.S. that's growing at a faster and more consistent pace than legal marijuana.Colorado, one of the eight states that's legalized....
TheMotleyFool 
0 05.11.17
3 Arguments for and Against Legalizing Marijuana
3 Arguments for and Against Legalizing Marijuana
There's arguably no industry in the U.S. that's growing at a faster, more consistent pace than legal marijuana. Marijuana Business Daily's latest report, "Marijuana Business Factbook 2017,"....
TheMotleyFool 
0 22.10.17
Why Marijuana Stocks Won't Pay a Dividend, Even if They're Profitable
Why Marijuana Stocks Won't Pay a Dividend, Even if They're Profitable
There aren't too many industries that can grow at 20%-plus a year over the next five years, but marijuana could be one of them. Cannabis research firm ArcView believes the legal North American pot....
TheMotleyFool 
0 20.10.17